What is the price of Tepotinib in Medicare?

Tepotinib as a tyrosine kinase inhibitor targetingMET gene mutations (especially exon 14 skipping mutations, METex14), has provided a new path for precision treatment for some patients with non-small cell lung cancer (NSCLC) in recent years. With its official launch in mainland China, the drug has also been included in the national medical insurance directory, which means that patients who meet the indication criteria can enjoy the corresponding medical insurance reimbursement policy, thus greatly reducing the financial burden.

According to public information, the original trade name of Tepotinib isTEPMETKO. The specification is 225mg tablets. The recommended dosage is two tablets once a day, totaling 450mg. The drug will be officially included in the National Reimbursement Directory in 2022, and the price has dropped after negotiations on the Reimbursement Directory. However, the specific personal out-of-pocket ratio after reimbursement still varies due to regional differences, medical insurance types, and whether the patient meets the clinical path.

Tepotinib achieves anti-tumor effects by selectively inhibiting the activity ofMET kinase and preventing the proliferation signals of tumor cells. Clinical studies have shown that the drug shows good efficacy in the treatment of METex14-positive non-small cell lung cancer, and can effectively reduce tumor burden and improve patients' quality of life. In addition, tepotinib is well tolerated. Common adverse reactions mainly include mild to moderate liver function abnormalities, rash, etc. Patients usually tolerate this treatment well.

In terms of price, the market price of tepotinib is generally within the range of 30,000 yuan. The actual cost may vary depending on the medical insurance reimbursement ratio and the patient's personal situation. For example, in some medical institutions, corresponding fee adjustments may be made based on the patient's specific medical insurance type and treatment plan. Overall, as an innovative drug, the introduction of tepotinib not only provides new hope for patients with METex14-positive non-small cell lung cancer, but also reflects my country's continuous efforts in the field of targeted tumor therapy.

Reference materials:https://www.tepotinib.com/